PR Center

홍보센터

회사소식

[Pulse]BIOMARKER-BASED ONCOLOGY DRUG DEVELOPER MEDPACTO SEEKS IPO

관리자2019-11-08조회 156

[Pulse]

MedPacto said on Thursday it is seeking initial public offering (IPO) in the local market under a special rule enabling money-losing yet promising startups to go public. Founded in 2013 in affiliation with Kosdaq-listed Theragen Etexas, MedPacto is a genome-based drug discovery and early clinical development company with an aim of bringing innovative therapies to those dealing with cancer and autoimmune disorders.

https://pulsenews.co.kr/view.php?year=2019&no=923115

첨부파일
검색 닫기